By Yafo Life Sciences
December 31st, 2021 (Shanghai) — We are glad to announce that Dr. Yongjiang Hei, the Co-CEO of Wuxi Biocity, has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.
If you are interested in listening to the live event, please register at https://biotochina.org/register/
About Wuxi Biocity
Wuxi Biocity was established in December 2017. It is an innovative drug company created by local entrepreneurs who have a deep understanding of the Chinese pharmaceutical market and young returned scientists relying on the world’s leading open drug innovation platform and ecology. Biocity is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated candidates (with no modality limitation) to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
About Dr. Yongjiang Hei
More than 20 years of clinical development and overall operational industry experience in large MNC and biotech companies in China and the United States.
Served as the medical director in Roche, Novartis, Amgen and other MNCs for a long time, and led the completion of clinical trials of new drugs with different modalities such as small molecules, macromolecules, and ADCs during his career.
Bachelor of Medicine, Shihezi University, Master of Pharmacology, West China University of Medical Sciences, PhD in Pharmacology, University of British Columbia, Canada.
About ACCESS CHINA
ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/
Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum
For more information, please contact: